257 related articles for article (PubMed ID: 35973578)
1. Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension.
Degasperi E; Anolli MP; Uceda Renteria SC; Sambarino D; Borghi M; Perbellini R; Scholtes C; Facchetti F; Loglio A; Monico S; Fraquelli M; Costantino A; Ceriotti F; Zoulim F; Lampertico P
J Hepatol; 2022 Dec; 77(6):1525-1531. PubMed ID: 35973578
[TBL] [Abstract][Full Text] [Related]
2. Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis.
Loglio A; Ferenci P; Uceda Renteria SC; Tham CYL; Scholtes C; Holzmann H; van Bömmel F; Borghi M; Perbellini R; Rimondi A; Farina E; Trombetta E; Manunta M; Porretti L; Prati D; Ceriotti F; Zoulim F; Bertoletti A; Lampertico P
J Hepatol; 2022 Feb; 76(2):464-469. PubMed ID: 34699951
[TBL] [Abstract][Full Text] [Related]
3. Bulevirtide for patients with compensated chronic hepatitis delta: A review.
Degasperi E; Anolli MP; Lampertico P
Liver Int; 2023 Aug; 43 Suppl 1():80-86. PubMed ID: 35942695
[TBL] [Abstract][Full Text] [Related]
4. Early virological response in six patients with hepatitis D virus infection and compensated cirrhosis treated with Bulevirtide in real-life.
Asselah T; Loureiro D; Le Gal F; Narguet S; Brichler S; Bouton V; Abazid M; Boyer N; Giuly N; Gerber A; Tout I; Maylin S; Bed CM; Marcellin P; Castelnau C; Gordien E; Mansouri A
Liver Int; 2021 Jul; 41(7):1509-1517. PubMed ID: 33999515
[TBL] [Abstract][Full Text] [Related]
5. Modelling HDV kinetics under the entry inhibitor bulevirtide suggests the existence of two HDV-infected cell populations.
Shekhtman L; Cotler SJ; Degasperi E; Anolli MP; Uceda Renteria SC; Sambarino D; Borghi M; Perbellini R; Facchetti F; Ceriotti F; Lampertico P; Dahari H
JHEP Rep; 2024 Feb; 6(2):100966. PubMed ID: 38274491
[TBL] [Abstract][Full Text] [Related]
6. Excellent safety and effectiveness of high-dose myrcludex-B monotherapy administered for 48 weeks in HDV-related compensated cirrhosis: A case report of 3 patients.
Loglio A; Ferenci P; Uceda Renteria SC; Tham CYL; van Bömmel F; Borghi M; Holzmann H; Perbellini R; Trombetta E; Giovanelli S; Greco L; Porretti L; Prati D; Ceriotti F; Lunghi G; Bertoletti A; Lampertico P
J Hepatol; 2019 Oct; 71(4):834-839. PubMed ID: 31302176
[TBL] [Abstract][Full Text] [Related]
7. Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide-results of a "real world" study.
Jachs M; Schwarz C; Panzer M; Binter T; Aberle SW; Hartl L; Dax K; Aigner E; Stättermayer AF; Munda P; Graziadei I; Holzmann H; Trauner M; Zoller H; Gschwantler M; Mandorfer M; Reiberger T; Ferenci P
Aliment Pharmacol Ther; 2022 Jul; 56(1):144-154. PubMed ID: 35514008
[TBL] [Abstract][Full Text] [Related]
8. Kinetics and predictive value of HBcrAg, HBV RNA and anti-HBc during bulevirtide treatment of chronic HDV-infected patients.
Sandmann L; Deterding K; Bremer B; Port K; Cornberg M; Wedemeyer H; Maasoumy B
J Viral Hepat; 2023 Apr; 30(4):283-286. PubMed ID: 36648369
[TBL] [Abstract][Full Text] [Related]
9. Bulevirtide with or without pegIFNα for patients with compensated chronic hepatitis delta: From clinical trials to real-world studies.
Lampertico P; Roulot D; Wedemeyer H
J Hepatol; 2022 Nov; 77(5):1422-1430. PubMed ID: 35752223
[TBL] [Abstract][Full Text] [Related]
10. "Real world" efficacy of bulevirtide in HBV/HDV-related cirrhosis including people living with HIV: Results from the compassionate use programme at INMI Spallanzani in Rome, Italy.
Visco Comandini U; De Santis E; De Maria F; Lionetti R; Taibi C; Montalbano M; Rianda A; Piccolo P; De Ponte C; Mazzotta S; Caioli A; Garbuglia AR; Maggi F; D'Offizi G
HIV Med; 2023 Oct; 24(10):1075-1082. PubMed ID: 37287427
[TBL] [Abstract][Full Text] [Related]
11. Quantification of serum HDV RNA by Robogene 2.0 in HDV patients is significantly influenced by the extraction methods.
Anolli MP; Renteria SU; Degasperi E; Borghi M; Facchetti F; Sambarino D; Perbellini R; Monico S; Ceriotti F; Lampertico P
Liver Int; 2024 Mar; 44(3):831-837. PubMed ID: 38247385
[TBL] [Abstract][Full Text] [Related]
12. Bile acid increase during bulevirtide treatment of hepatitis D is not associated with a decline in HDV RNA.
Deterding K; Xu C; Port K; Dietz-Fricke C; Xun J; Maasoumy B; Cornberg M; Wedemeyer H
J Viral Hepat; 2023 Jul; 30(7):597-606. PubMed ID: 36924318
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis D: A Review.
Negro F; Lok AS
JAMA; 2023 Dec; 330(24):2376-2387. PubMed ID: 37943548
[TBL] [Abstract][Full Text] [Related]
14. No virologic resistance to bulevirtide monotherapy detected in patients through 24 weeks treatment in phase II and III clinical trials for chronic hepatitis delta.
Hollnberger J; Liu Y; Xu S; Chang S; Martin R; Manhas S; Aeschbacher T; Han B; Yazdi T; May L; Han D; Shornikov A; Flaherty J; Manuilov D; Suri V; Asselah T; Lampertico P; Wedemeyer H; Aleman S; Richards C; Mateo R; Maiorova E; Cihlar T; Mo H; Urban S
J Hepatol; 2023 Sep; 79(3):657-665. PubMed ID: 37120031
[TBL] [Abstract][Full Text] [Related]
15. Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies.
Allweiss L; Volmari A; Suri V; Wallin JJ; Flaherty JF; Manuilov D; Downie B; Lütgehetmann M; Bockmann JH; Urban S; Wedemeyer H; Dandri M
J Hepatol; 2024 Jun; 80(6):882-891. PubMed ID: 38340811
[TBL] [Abstract][Full Text] [Related]
16. Real-life experiences with bulevirtide for the treatment of hepatitis delta-48 weeks data from a German centre.
Zöllner C; Hofmann J; Lutz K; Tacke F; Demir M
Liver Int; 2022 Nov; 42(11):2403-2407. PubMed ID: 36004554
[TBL] [Abstract][Full Text] [Related]
17. A 3-Year Course Of Bulevirtide Monotherapy May Cure Hdv Infection In Cirrhotics.
Anolli MP; Degasperi E; Allweiss L; Sangiovanni A; Maggioni M; Scholtes C; Oberhardt V; Neumann-Haefelin C; Dandri M; Zoulim F; Lampertico P
J Hepatol; 2023 Jan; ():. PubMed ID: 36931396
[TBL] [Abstract][Full Text] [Related]
18. Bulevirtide in the Treatment of Hepatitis Delta: Drug Discovery, Clinical Development and Place in Therapy.
Soriano V; Moreno-Torres V; Treviño A; Corral O; de Mendoza C
Drug Des Devel Ther; 2023; 17():155-166. PubMed ID: 36712949
[TBL] [Abstract][Full Text] [Related]
19. A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D.
Wedemeyer H; Aleman S; Brunetto MR; Blank A; Andreone P; Bogomolov P; Chulanov V; Mamonova N; Geyvandova N; Morozov V; Sagalova O; Stepanova T; Berger A; Manuilov D; Suri V; An Q; Da B; Flaherty J; Osinusi A; Liu Y; Merle U; Schulze Zur Wiesch J; Zeuzem S; Ciesek S; Cornberg M; Lampertico P;
N Engl J Med; 2023 Jul; 389(1):22-32. PubMed ID: 37345876
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Albrecht J; Schmid P; Le Gal F; Gordien E; Krawczyk A; Mijočević H; Karimzadeh H; Roggendorf M; Vaillant A
Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):877-889. PubMed ID: 28964701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]